Literature DB >> 17607916

Resistance to chemotherapy in ovarian carcinoma.

Hermann Lage1, Carsten Denkert.   

Abstract

Resistance to cytotoxic chemotherapy is the main cause of therapeutic failure and death in women suffering from ovarian carcinoma. The standard first-line chemotherapy of ovarian cancer consists of a combination of a taxane and a platinum-containing drug. Thus, the cellular and molecular mechanisms involved in resistance against these compounds are of vital importance in the context of chemotherapy of ovarian cancer. This review will discuss the current state of knowledge of drug resistance-associated factors and their impact on clinical chemotherapy response in ovarian carcinoma as well as different strategies for reversal of drug resistance.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17607916     DOI： 10.1007/978-3-540-46091-6_6

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN： 0080-0015


  11 in total

1.  FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway.

Authors:  Ya-Kun Liu; Ya-Jing Jia; Shi-Hao Liu; Jing Ma
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-03       Impact factor: 3.333

2.  Epithelial ovarian cancer stem cells-a review.

Authors:  Yueyin Pan; Xudong Huang
Journal:  Int J Clin Exp Med       Date:  2008-06-30

3.  Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha.

Authors:  Lei Huang; Qilin Ao; Qinghua Zhang; Xiaokui Yang; Hui Xing; Fang Li; Gang Chen; Jianfeng Zhou; Shixuan Wang; Gang Xu; Li Meng; Yunping Lu; Ding Ma
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-16       Impact factor: 4.553

4.  Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.

Authors:  Ning Xu; Zhihong Zhang; Jin Zhu; Lu Xu; Yuhua Li; Lei Duan; Yuan Mao; Hongxia Li
Journal:  Int J Exp Pathol       Date:  2016-04-29       Impact factor: 1.925

5.  BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.

Authors:  J L Lesnock; K M Darcy; C Tian; J A Deloia; M M Thrall; C Zahn; D K Armstrong; M J Birrer; T C Krivak
Journal:  Br J Cancer       Date:  2013-03-05       Impact factor: 7.640

6.  A seven-gene prognostic model for platinum-treated ovarian carcinomas.

Authors:  R Sabatier; P Finetti; J Bonensea; J Jacquemier; J Adelaide; E Lambaudie; P Viens; D Birnbaum; F Bertucci
Journal:  Br J Cancer       Date:  2011-06-07       Impact factor: 7.640

7.  PRP4K is a HER2-regulated modifier of taxane sensitivity.

Authors:  Dale P Corkery; Cécile Le Page; Liliane Meunier; Diane Provencher; Anne-Marie Mes-Masson; Graham Dellaire
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 8.  Dysregulated Expression of Long Noncoding RNAs in Ovarian Cancer.

Authors:  Yancheng Zhong; Dan Gao; Shiwei He; Cijun Shuai; Shuping Peng
Journal:  Int J Gynecol Cancer       Date:  2016-11       Impact factor: 3.437

9.  2-methoxyestradiol mediates apoptosis through caspase-dependent and independent mechanisms in ovarian cancer cells but not in normal counterparts.

Authors:  Sumie Kato; Anil Sadarangani; Soledad Lange; Ana M Delpiano; Macarena Vargas; Jorge Brañes; Jorge Carvajal; Stanley Lipkowitz; Gareth I Owen; Mauricio A Cuello
Journal:  Reprod Sci       Date:  2008-11       Impact factor: 3.060

10.  Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.

Authors:  Yi Zhang; Jianfang Liu; Praveen-Kumar Raj-Kumar; Lori A Sturtz; Anupama Praveen-Kumar; Howard H Yang; Maxwell P Lee; J Leigh Fantacone-Campbell; Jeffrey A Hooke; Albert J Kovatich; Craig D Shriver; Hai Hu
Journal:  Breast Cancer Res Treat       Date:  2020-09-02       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.